AtaiBeckley Inc.

Contributing Author

Recent Articles by AtaiBeckley Inc.

Jul-06	AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder ATAI GlobeNewswire
Jun-25	AtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets ATAI +9.83% GlobeNewswire
May-28	AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations ATAI GlobeNewswire
May-27	AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026 ATAI GlobeNewswire
May-12	AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update ATAI GlobeNewswire
Apr-27	AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research ATAI -6.26% GlobeNewswire
Apr-08	AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs ATAI GlobeNewswire
Mar-24	AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst ATAI GlobeNewswire
Mar-17	BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation ATAI GlobeNewswire
Mar-10	BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day ATAI +6.43% GlobeNewswire
Mar-06	AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update ATAI GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)